McIlwain Matthew S's Form 4 filing
Nautilus Biotechnology, Inc. (NAUT) · filed Aug 26, 2021
- Accession no.
- 0001062993-21-007983
- Filed
- Aug 26, 2021
- Trade date
- Aug 24-26, 2021
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market purchases total $285.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| McIlwain Matthew SCIK 0001381752 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 24, 2021 | Common Stock | PPurchaseAcquired | +13,568 | $7.68 | +$104,202.24 | 335,673 | Direct | |
| Aug 25, 2021 | Common Stock | PPurchaseAcquired | +11,693 | $7.74 | +$90,503.82 | 347,366 | Direct | |
| Aug 26, 2021 | Common Stock | PPurchaseAcquired | +11,709 | $7.71 | +$90,276.39 | 359,075 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.